517
Views
11
CrossRef citations to date
0
Altmetric
Research Article

A study on bone cement containing magnesium potassium phosphate for bone repair

, , , , , , , , & | (Reviewing editor) show all
Article: 1487255 | Received 28 Sep 2017, Accepted 07 Jun 2018, Published online: 28 Jun 2018
 

Abstract

A novel type of bone cement, magnesium potassium phosphate cement (MKPC), was fabricated by mixing 5% phosphoric acid with magnesia, potassium dihydrogen phosphate, sucrose, hydroxyapatite, and sodium tri-polyphosphate powders. The surface morphology and mechanical strength of MKPC were investigated together with tissue responses following implantation into rabbit condylar defects, using commercially available calcium phosphate cement (CPC) as the control. The results showed that MKPC had a higher compressive strength (25.40 ± 0.61 MPa) than CPC (16.45 ± 1.91 Mpa) and did not initiate foreign body reaction, inflammation, or necrosis in vivo. Both cements were resorbed by creeping substitution, in which the resorbed cement was replaced by the newly formed bone. MKPC had a higher resorption rate and enhanced bone regeneration compared to CPC. The data presented here indicate that MKPC could be a potential bone void filler for bio-adhesion in clinical applications.

Additional information

Funding

This work was supported by the project of Youth Science and Technology Innovation Team of Sichuan Province, China [2017TD0008]; Innovation Team Project of Education Department of Sichuan Province [16TD0020]; major project of education department in Sichuan Province, China [18CZ0019].

Notes on contributors

Zaijun Yang

Prof. Zaijun Yang has been working in the field of inorganic biomaterial development and biological evaluation for past five years and their laboratory is part of collaboration innovation center for tissue repair material engineering technology, China West Normal University. This center is mainly engaged in the research and development of biomaterials and biological evaluation. At present, the center has four independent intellectual property products into clinical trials.